Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13159744 | 0.86 | HDAC1 (0.72) | MMP8HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL8082660 | 0.84 | MEN1 (0.86) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL8312047 | 0.81 | HDAC1 (0.70) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL13928115 | 0.81 | HDAC1 (0.70) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL8296132 | 0.81 | MMP8 (0.70) | MMP8EPHX2 | |
| SCHEMBL30199483 | 0.80 | MMP1 (0.66) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL8200430 | 0.80 | HDAC2 (0.77) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL13928112 | 0.80 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL8312589 | 0.80 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL13786403 | 0.78 | MEN1 (0.66) | MEN1KMT2AHDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | MMP8 1006/4885MEN1 2750/4885KMT2A 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.